Vera Therapeutics, Inc. (NASDAQ:VERA), a commercial-stage biotechnology company, today announced that there will be multiple presentations at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, from October 22 to 25. The final efficacy analysis of the ORIGIN 3 trial of TRUTAKNA in IgA nephropathy (IgAN) will be a featured late-breaking oral presentation during the opening plenary session and also a late-breaking research poster. In addition, interim results from the adult IgAN and primary membranous nephropathy (pMN) cohorts in PIONEER, a Phase 2 basket trial of atacicept in multiple glomerular diseases, will be a late-breaking research oral presentation. In total, five Vera sponsored abstracts will be presented at ASN Kidney Week 2026, demonstrating the Company’s commitment to transforming medicine in autoimmune kidney disease.